Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Main billing specialties: cardiology and electrophysiology.
Medicare fee-for-service LAA occlusion & loop recorders cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 310 | 13,955+10%/yr | +10%/yr | 5.31.6× | 38% | 26,400 in 2030+11%/yr |
| California | 227 | 10,060+12%/yr | +12%/yr | 2.60.8× | 33% | 20,000 in 2030+12%/yr |
| Texas | 217 | 9,542+12%/yr | +12%/yr | 3.81.2× | 18% | 18,100 in 2030+11%/yr |
| New York | 191 | 8,988+5.9%/yr | +5.9%/yr | 4.31.3× | 12% | 14,400 in 2030+8.1%/yr |
| Pennsylvania | 139 | 4,787+8.9%/yr | +8.9%/yr | 3.00.9× | 14% | 7,520 in 2030+7.8%/yr |
| Arizona | 106 | 4,739+15%/yr | +15%/yr | 5.61.7× | 41% | 7,950 in 2030+9%/yr |
| Illinois | 125 | 4,051+13%/yr | +13%/yr | 2.60.8× | 15% | 6,990 in 2030+9.5%/yr |
| New Jersey | 90 | 3,940+7.1%/yr | +7.1%/yr | 3.41.0× | 37% | 6,480 in 2030+8.7%/yr |
| South Carolina | 71 | 3,614+14%/yr | +14%/yr | 4.71.4× | 11% | 6,460 in 2030+10%/yr |
| Ohio | 94 | 3,603+4.6%/yr | +4.6%/yr | 2.80.9× | 1% | 6,180 in 2030+9.4%/yr |
| Virginia | 85 | 3,380+18%/yr | +18%/yr | 2.90.9× | 19% | 6,100 in 2030+10%/yr |
| Michigan | 82 | 3,065+2.7%/yr | +2.7%/yr | 3.10.9× | 17% | 4,880 in 2030+8.1%/yr |
| Tennessee | 70 | 2,864+9.6%/yr | +9.6%/yr | 3.51.1× | 3% | 5,150 in 2030+10%/yr |
| Georgia | 70 | 2,787+8.8%/yr | +8.8%/yr | 2.80.9× | 7% | 5,510 in 2030+12%/yr |
| North Carolina | 76 | 2,760+8.6%/yr | +8.6%/yr | 2.40.7× | 7% | 4,660 in 2030+9.1%/yr |
| Indiana | 68 | 2,697+18%/yr | +18%/yr | 3.31.0× | 0% | 4,650 in 2030+9.5%/yr |
| Kansas | 56 | 2,663+15%/yr | +15%/yr | 6.01.9× | 5% | 4,850 in 2030+10%/yr |
| Massachusetts | 67 | 2,548+8.4%/yr | +8.4%/yr | 2.40.8× | 8% | 4,890 in 2030+11%/yr |
| Missouri | 58 | 2,381+6.1%/yr | +6.1%/yr | 3.31.0× | 1% | 3,950 in 2030+8.8%/yr |
| Washington | 46 | 2,007+11%/yr | +11%/yr | 2.30.7× | 2% | 3,420 in 2030+9.3%/yr |
| Oklahoma | 50 | 1,926+8.2%/yr | +8.2%/yr | 3.61.1× | 8% | 3,560 in 2030+11%/yr |
| Colorado | 39 | 1,871+12%/yr | +12%/yr | 3.31.0× | 4% | 4,220 in 2030+15%/yr |
| Wisconsin | 50 | 1,796+14%/yr | +14%/yr | 2.70.8× | 0% | 3,250 in 2030+10%/yr |
| Maryland | 56 | 1,696+8.1%/yr | +8.1%/yr | 1.80.6× | 35% | 3,080 in 2030+10%/yr |
| Mississippi | 37 | 1,533+9.3%/yr | +9.3%/yr | 3.61.1× | 28% | 2,480 in 2030+8.3%/yr |
| Alabama | 39 | 1,517+9.2%/yr | +9.2%/yr | 2.90.9× | 6% | 2,190 in 2030+6.3%/yr |
| Louisiana | 39 | 1,487+8.4%/yr | +8.4%/yr | 3.11.0× | 11% | 2,580 in 2030+9.6%/yr |
| Minnesota | 42 | 1,476+9.6%/yr | +9.6%/yr | 2.80.8× | 3% | 3,650 in 2030+16%/yr |
| Arkansas | 24 | 1,335+7.5%/yr | +7.5%/yr | 3.11.0× | 0% | 2,590 in 2030+12%/yr |
| Kentucky | 42 | 1,148+5.9%/yr | +5.9%/yr | 2.20.7× | 0% | 2,100 in 2030+11%/yr |
| Nebraska | 22 | 1,071+16%/yr | +16%/yr | 3.81.2× | 3% | 1,730 in 2030+8.3%/yr |
| Connecticut | 35 | 1,043+11%/yr | +11%/yr | 2.70.8× | 5% | 1,680 in 2030+8.2%/yr |
| Iowa | 21 | 859+11%/yr | +11%/yr | 1.80.5× | 5% | 1,760 in 2030+13%/yr |
| Idaho | 16 | 740+15%/yr | +15%/yr | 3.21.0× | 0% | 1,470 in 2030+12%/yr |
| Oregon | 19 | 718+9.3%/yr | +9.3%/yr | 1.50.5× | 5% | 1,330 in 2030+11%/yr |
| Utah | 21 | 682+17%/yr | +17%/yr | 2.70.8× | 16% | 1,130 in 2030+8.9%/yr |
| Nevada | 14 | 673+17%/yr | +17%/yr | 2.00.6× | 16% | 1,740 in 2030+17%/yr |
| West Virginia | 16 | 642+15%/yr | +15%/yr | 2.60.8× | 0% | 980 in 2030+7.4%/yr |
| Delaware | 17 | 625+4.5%/yr | +4.5%/yr | 3.31.0× | 31% | 810 in 2030+4.3%/yr |
| North Dakota | 15 | 600+12%/yr | +12%/yr | 5.51.7× | 0% | 1,190 in 2030+12%/yr |
| New Hampshire | 16 | 537+13%/yr | +13%/yr | 2.10.7× | 11% | 1,450 in 2030+18%/yr |
| South Dakota | 11 | 481+17%/yr | +17%/yr | 3.41.0× | 0% | 890 in 2030+11%/yr |
| New Mexico | 5 | 431+11%/yr | +11%/yr | 1.60.5× | 2% | 1,040 in 2030+16%/yr |
| Montana | 12 | 395+13%/yr | +13%/yr | 1.90.6× | 0% | 760 in 2030+11%/yr |
| District of Columbia | 8 | 352+11%/yr | +11%/yr | 5.11.6× | 43% | 630 in 2030+10%/yr |
| Maine | 13 | 319+15%/yr | +15%/yr | 1.70.5× | 0% | 450 in 2030+5.7%/yr |
| Rhode Island | 5 | 246−0.3%/yr | −0.3%/yr | 2.30.7× | 0% | 350 in 2030+6.1%/yr |
| Vermont | 3 | 103−6.7%/yr | −6.7%/yr | 0.80.3× | 0% | 200 in 2030+12%/yr |
| Alaska | 4 | 103+2.1%/yr | +2.1%/yr | 0.80.3× | 39% | 120 in 2030+2.5%/yr |
Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 120 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 4 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Boston Scientific | 77 |
| Abbott | 22 |
| Medtronic | 13 |
| Biotronik | 8 |
Product codes: MXD (recorder, event, implantable cardiac, (with arrhythmia detection)), NGV (system, appendage closure, left atrial). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +3 pts since 2019, to 18%.
The 10 busiest do 14% of the cases CMS names in Florida; 167 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 3,039 | 159,222−3.4%/yr | −3.4%/yr | 164,900 in 2030+0.6%/yr |
| EP ablation | 2,323 | 129,831+7.2%/yr | +7.2%/yr | 241,600 in 2030+11%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 6 companies reported engagement with surgeons in the covered states worth $7.8M in consulting, speaking, meals and travel tied to these products, about $2,670 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.